Uterine Sarcoma

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Uterine Sarcoma

MalaCards integrated aliases for Uterine Sarcoma:

Name: Uterine Sarcoma 53 55 17
Uterine Corpus Sarcoma 72
Sarcoma of the Uterus 53


External Ids:

UMLS 72 C0338113

Summaries for Uterine Sarcoma

MalaCards based summary : Uterine Sarcoma, also known as uterine corpus sarcoma, is related to leukemia, acute myeloid and sarcoma. An important gene associated with Uterine Sarcoma is ABCB1 (ATP Binding Cassette Subfamily B Member 1), and among its related pathways/superpathways are MicroRNAs in cancer and Retinoblastoma (RB) in Cancer. The drugs Doxorubicin and Mesna have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and breast, and related phenotypes are Decreased cell proliferation and endocrine/exocrine gland

Wikipedia : 75 The uterine sarcomas form a group of malignant tumors that arises from the smooth muscle or connective... more...

Related Diseases for Uterine Sarcoma

Diseases related to Uterine Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 29.0 WT1 DCK ABCB1
2 sarcoma 11.0
3 spindle cell sarcoma 11.0
4 leiomyosarcoma 11.0
5 endometrial stromal sarcoma 10.8
6 carcinosarcoma 10.8
7 leiomyoma 10.6
8 adenosarcoma 10.5
9 endometrial cancer 10.4
10 myoma 10.4
11 myofibroma 10.4
12 leiomyoma, uterine 10.3
13 uterine inversion 10.3
14 rhabdomyosarcoma 10.3
15 embryonal sarcoma 10.3
16 myeloid sarcoma 10.3
17 adenocarcinoma 10.3
18 mesenchymal cell neoplasm 10.2
19 soft tissue sarcoma 10.2
20 neutropenia 10.2
21 endometrial adenocarcinoma 10.2
22 uterine carcinosarcoma 10.2
23 overgrowth syndrome 10.2
24 endometrial stromal tumor 10.1
25 sarcomatosis 10.1
26 rare tumor 10.1
27 osteogenic sarcoma 10.1
28 alveolar soft part sarcoma 10.1
29 lymphoma 10.1
30 microsporidiosis 10.1 ABCC1 ABCB1
31 breast cancer 10.1
32 colchicine resistance 10.1 ABCC1 ABCB1
33 angiosarcoma 10.0
34 small cell carcinoma 10.0
35 fibrosarcoma 10.0
36 vaginal discharge 10.0
37 myelodysplastic syndrome 10.0
38 cervix carcinoma 10.0 ABCC1 ABCB1
39 hemangiopericytoma, malignant 9.9
40 adenomyosis 9.9
41 cervical cancer 9.9
42 meningioma, radiation-induced 9.9
43 meningioma, familial 9.9
44 rhabdoid tumor predisposition syndrome 1 9.9
45 endometritis 9.9
46 spinal meningioma 9.9
47 thrombocytopenia 9.9
48 embryonal rhabdomyosarcoma 9.9
49 liposarcoma 9.9
50 rhabdoid cancer 9.9

Graphical network of the top 20 diseases related to Uterine Sarcoma:

Diseases related to Uterine Sarcoma

Symptoms & Phenotypes for Uterine Sarcoma

GenomeRNAi Phenotypes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell proliferation GR00353-A 8.62 CDK2 DCK

MGI Mouse Phenotypes related to Uterine Sarcoma:

# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.65 ABCB1 CCND2 CDK2 DCK WT1
2 hematopoietic system MP:0005397 9.63 ABCB1 ABCC1 CCND2 CDK2 DCK WT1
3 immune system MP:0005387 9.43 ABCB1 ABCC1 CCND2 CDK2 DCK WT1
4 liver/biliary system MP:0005370 8.92 ABCB1 CCND2 CDK2 WT1

Drugs & Therapeutics for Uterine Sarcoma

Drugs for Uterine Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
Mesna Approved, Investigational Phase 3 3375-50-6 598
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Gemcitabine Approved Phase 3 95058-81-4 60750
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
Lenograstim Approved, Investigational Phase 3 135968-09-1
Bevacizumab Approved, Investigational Phase 3 216974-75-3
Histamine Approved, Investigational Phase 3 51-45-6 774
Cyproheptadine Approved Phase 3 129-03-3 2913
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
12 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
13 Antibiotics, Antitubercular Phase 3
Liposomal doxorubicin Phase 3 31703
15 Analgesics Phase 3
16 Peripheral Nervous System Agents Phase 3
17 Cola Phase 3
18 Anesthetics, Intravenous Phase 3
19 Narcotics Phase 3
20 Adjuvants, Anesthesia Phase 3
21 Central Nervous System Depressants Phase 3
22 Anesthetics Phase 3
23 Anesthetics, General Phase 3
24 Analgesics, Opioid Phase 3
25 DHEA (Dehydroepiandrosterone) Phase 3
26 Immunologic Factors Phase 3
27 Antimetabolites Phase 3
28 Antimetabolites, Antineoplastic Phase 3
29 Antiviral Agents Phase 3
30 Adjuvants, Immunologic Phase 3
31 Angiogenesis Inhibitors Phase 3
32 Angiogenesis Modulating Agents Phase 3
33 Immunoglobulin G Phase 3
34 Mitogens Phase 3
35 Antineoplastic Agents, Immunological Phase 3
36 Antibodies Phase 3
37 Immunoglobulins Phase 3
38 Endothelial Growth Factors Phase 3
39 Antibodies, Monoclonal Phase 3
40 Gastrointestinal Agents Phase 3
41 Neurotransmitter Agents Phase 3
42 Anti-Allergic Agents Phase 3
43 Serotonin Antagonists Phase 3
44 Histamine H1 Antagonists Phase 3
45 Histamine Antagonists Phase 3
46 Dermatologic Agents Phase 3
47 Serotonin Agents Phase 3
Histamine Phosphate Phase 3 51-74-1 65513
49 Antipruritics Phase 3
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
2 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
3 A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma Unknown status NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
4 A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
5 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
6 A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
8 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
10 A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III Completed NCT00002706 Phase 3
11 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
12 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
14 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
15 A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment Unknown status NCT01979393 Phase 2 Cabozantinib;Placebo
16 A Phase II Study of Combination Therapy of a Protracted Oral Schedule of Temozolomide and Thalidomide as First-Line or Subsequent Therapy for Patients With Metastatic, Locally Advanced or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
17 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
18 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
19 Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers Unknown status NCT02052128 Phase 1, Phase 2 onapristone
20 Systematic Nutritional Care in Patients Receiving First-line Chemotherapy for Metastatic Gynecologic Cancer in a Phase II Study Unknown status NCT00905658 Phase 2
21 Evaluation of Doxil in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
22 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01168232 Phase 2 Ixabepilone
23 A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
24 A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
25 A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
26 A Phase II Evaluation of Docetaxel and Gemcitabine Plus G-CSF in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
27 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01220609 Phase 2 Ixabepilone
28 Phase II Study of Thalidomide (NSC #66847) in Patients With Sarcomas of Gynecologic Origin Completed NCT00006005 Phase 2 thalidomide
29 A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00112489 Phase 2 carboplatin;paclitaxel
30 Continuous 5 Days Infusion of High Dose Ifosfamide and Adriamycin in Patients With Advanced Sarcoma Completed NCT00002526 Phase 2 doxorubicin hydrochloride;ifosfamide
31 A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas Completed NCT00379145 Phase 2 trabectedin
32 Phase I/II Trial, Dose Finding Combination Chemotherapy With PegLiposomal Doxorubicin (PLD) And Carboplatin In Patients With Gynecologic Tumors Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
33 A Phase II Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
34 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
35 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
36 Phase II Trial of Dolastatin-10 in Patients With Previously Untreated Recurrent/Metastatic Sarcoma Completed NCT00003778 Phase 2 dolastatin 10
37 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
38 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
39 Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas Completed NCT00227669 Phase 2 docetaxel;gemcitabine hydrochloride
40 A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma Completed NCT00238121 Phase 2 sorafenib tosylate
41 A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
42 Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
43 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
44 Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial Completed NCT00381888 Phase 2 fondaparinux sodium
45 A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
46 A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00075400 Phase 2 imatinib mesylate
47 A Phase II Trial of Radiosurgery for 1 to 3 Newly Diagnosed Brain Metastases From Renal Cell, Melanoma and Sarcoma Completed NCT00003308 Phase 2
48 High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
49 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
50 A Phase II Investigation of Pembrolizumab (Keytruda) in Combination With Radiation and an Immune Modulatory Cocktail in Patients With Cervical and Uterine Cancer (PRIMMO Trial) Recruiting NCT03192059 Phase 2 Pembrolizumab;Vitamin D;Aspirin;Lansoprazole;Cyclophosphamide

Search NIH Clinical Center for Uterine Sarcoma

Genetic Tests for Uterine Sarcoma

Anatomical Context for Uterine Sarcoma

MalaCards organs/tissues related to Uterine Sarcoma:

Uterus, Smooth Muscle, Breast, Bone, Lung, Brain, Endothelial

Publications for Uterine Sarcoma

Articles related to Uterine Sarcoma:

(show top 50) (show all 888)
# Title Authors PMID Year
Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature. 9 38
20122944 2010
Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. 9 38
20487633 2010
Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression. 9 38
19617332 2009
Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells. 9 38
18845169 2008
Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. 9 38
18813811 2008
Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells. 9 38
18625294 2008
Distinct N-glycan glycosylation of P-glycoprotein isolated from the human uterine sarcoma cell line MES-SA/Dx5. 9 38
17692467 2007
PDGFR-alpha as a potential therapeutic target in uterine sarcomas. 9 38
17049587 2007
Prognostic factors and expression of p53 and mdm-2 in uterine sarcomas. 9 38
16930603 2006
Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody. 9 38
16832635 2006
Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. 9 38
15921732 2005
Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells. 9 38
10867652 2000
Overexpression of carbonyl reductase 1 inhibits malignant behaviors and epithelial mesenchymal transition by suppressing TGF-β signaling in uterine leiomyosarcoma cells. 38
31423217 2019
[Clinicopathological study of BCOR rearrangement in high grade endometrial stromal sarcoma]. 38
31422590 2019
Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy. 38
30853364 2019
Prediction of Occult Uterine Sarcoma prior to Hysterectomy for Women with Leiomyoma or Abnormal Bleeding. 38
31352067 2019
Current status of the adjuvant therapy in uterine sarcoma: A literature review. 38
31417921 2019
Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study. 38
31307426 2019
Prognostic factors, survival outcomes and surgical practices when dealing with uterine sarcomas: 8 years of clinical experience 38
31298514 2019
Diagnostic value of 3 T MR spectroscopy, diffusion-weighted MRI, and apparent diffusion coefficient value for distinguishing benign from malignant myometrial tumours. 38
31010584 2019
Adjuvant management of operated uterine sarcomas: A single institution experience. 38
31351809 2019
Chemo-sensitizing activity of natural cadinanes from Heterotheca inuloides in human uterine sarcoma cells and their in silico interaction with ABC transporters. 38
31319298 2019
Uterine sarcomas. 38
31235185 2019
Uterine Sarcomas: Experience from a Tertiary Cancer Care Center from India. 38
31168260 2019
Preliminary utilization of radiomics in differentiating uterine sarcoma from atypical leiomyoma: Comparison on diagnostic efficacy of MRI features and radiomic features. 38
31084757 2019
SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association. 38
31190001 2019
Uterine Mesenchymal Tumors: Update on Classification, Staging, and Molecular Features. 38
31097109 2019
Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group. 38
30772825 2019
PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. 38
31138229 2019
A more accurate method to interpret lactate dehydrogenase (LDH) isoenzymes' results in patients with uterine masses. 38
30925450 2019
High grade sarcoma, with predominant neuroectodermal and minor embryonal rhabdomyosarcomatous tumor of the uterus: A case report. 38
31032392 2019
Allopurinol, furosemide and a phytotherapeutic agent (Bazoton uno) reverse P-glycoprotein-mediated doxorubicin resistance in human uterine sarcoma MES-SA/Dx5 cells: a novel therapeutic perspective. 38
31162035 2019
Undifferentiated Uterine Sarcomas Represent Under-Recognized High-grade Endometrial Stromal Sarcomas. 38
30789359 2019
The Effect of Fucoidan, a Potential New, Natural, Anti-Neoplastic Agent on Uterine Sarcomas and Carcinosarcoma Cell Lines: ENITEC Collaborative Study. 38
30659312 2019
Non-puerperal uterine inversion associated with adenosarcoma of the uterus: A case report. 38
30923682 2019
Role of surgery in gynaecological sarcomas. 38
31069017 2019
Pleomorphic Undifferentiated Uterine Sarcoma in a Young Patient Presenting With Elevated Beta-hCG and Rare Variants of Benign Leiomyoma: A Case Report and Review of the Literature. 38
31033798 2019
Correction to: Reply to ''Comments on ''Magnetic resonance imaging features of uterine sarcoma and mimickers''. 38
30328485 2019
Preoperative Differentiation of Uterine Sarcoma from Leiomyoma: Comparison of Three Models Based on Different Segmentation Volumes Using Radiomics. 38
30850967 2019
Resveratrol suppresses proliferation and induces apoptosis of uterine sarcoma cells by inhibiting the Wnt signaling pathway. 38
30867708 2019
Actinomycotic Endometritis. 38
29369919 2019
Imaging of gynecological disease: clinical and ultrasound characteristics of uterine sarcomas. 38
30908820 2019
Prognostic factors associated with uterine sarcomas: the experience of a single institution. 38
30354797 2019
Reversing multi-drug tumor resistance to Paclitaxel by well-defined pH-sensitive amphiphilic polypeptide block copolymers via induction of lysosomal membrane permeabilization. 38
30408674 2019
A Pilot Prospective Study of Refractory Solid Tumor Patients for NGS-Based Targeted Anticancer Therapy. 38
30448735 2019
Letter to the editor regarding the article "Magnetic resonance imaging features of uterine sarcoma and mimickers". 38
30267106 2019
A multiparametric MRI-based machine learning to distinguish between uterine sarcoma and benign leiomyoma: comparison with 18F-FDG PET/CT. 38
30471748 2019
Results of an internal audit on the survival of patients with uterine sarcoma 38
30299262 2019
Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study. 38
30447212 2019
Reply to "Comments on "Magnetic resonance imaging features of uterine sarcoma and mimickers". 38
30255445 2019

Variations for Uterine Sarcoma

Expression for Uterine Sarcoma

Search GEO for disease gene expression data for Uterine Sarcoma.

Pathways for Uterine Sarcoma

GO Terms for Uterine Sarcoma

Cellular components related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein kinase holoenzyme complex GO:0000307 8.62 CDK2 CCND2

Biological processes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G2/M transition of mitotic cell cycle GO:0000086 9.26 CDK2 ABCB1
2 phospholipid translocation GO:0045332 9.16 ABCC1 ABCB1
3 drug transmembrane transport GO:0006855 8.65 ABCC1
4 xenobiotic transport GO:0042908 8.32 ABCC1

Molecular functions related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.46 DCK CDK2 ABCC1 ABCB1
2 transporter activity GO:0005215 8.96 ABCB1
3 ATPase activity, coupled to transmembrane movement of substances GO:0042626 8.96 ABCC1 ABCB1
4 xenobiotic transmembrane transporting ATPase activity GO:0008559 8.62 ABCC1 ABCB1

Sources for Uterine Sarcoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....